Human-grade BPC-157 is produced by licensed compounding pharmacies under strict purity, sterility, and potency standards intended for patient use
Drug-microbiota interactions: an emerging priority for precision medicine
The starting dose of 0.3 mg represents approximately 6.7% of the final maintenance dosea conservative approach that prioritizes safety
This product is supplied as a 99.9% pure lyophilized (freeze-dried) powder in vial strengths from 2 mg to 20 mg, designed for precise measuring and stable storage before reconstitution
References: NCBI Research on BPC-157
All SAEs of death, development of signs of critical illness and severe illness requiring hospitalisation, and AEs as described previously will be reported to the Ethics Committees, the Data and Safety Monitoring Board (DSMB) and to the sponsors of the study within 24 hours of awareness of the event, followed by a final report within 10 days